Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LifeStream Adds Neonatal, Pediatric Oxygenators With Polystan Acquisition

This article was originally published in The Gray Sheet

Executive Summary

The addition of Polystan's SAFE Micro neonatal oxygenator to LifeStream's product line will help boost annual revenue by $15 mil. to over $100 mil. following the company's acquisition of the Vaerlose, Denmark-based company.

You may also be interested in...

Financiers Piecing Together New Cardiopulmonary Device Maker

LifeStream International is looking to capture as much as 10% of the cardiopulmonary market following the launch of the firm in the second half of 1999.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts